The combined HRs for 14 studies evaluating MET overexpression on overall survival was 2.57 (95% CI: 1.97–3.35), suggesting that MET overexpression was an indicator of poor prognosis for gastric cancer (Fig. 2). Here, MET is linked to gastric cancer.